AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28182863 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-delivered diabetes self-management intervention
Number of subjects: 287
Study 28182863 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 287
Study 25486375 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Guidance (VIG)
Number of subjects: 150
Study 25486375 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 150
Study 24027945 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated suppression group (3 suppression and 3 think free phases)
Number of subjects: 0
Study 24027945 — intervention group
Group type: COMPARATOR
Intervention: Suppress think free group (1 suppression phase followed by 5 think free phases)
Number of subjects: 0
Study 22029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery care
Number of subjects: 750
Study 22029746 — intervention group
Group type: COMPARATOR
Intervention: Standard or routine hospital care
Number of subjects: 750
Study 19285581 — intervention group
Group type: EXPERIMENTAL
Intervention: No Lifting policy intervention
Number of subjects: 0
Study 19285581 — intervention group
Group type: COMPARATOR
Intervention: Before and after intervention periods
Number of subjects: 0
Study 17016713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.25 mg
Number of subjects: 15
Study 17016713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 15
Study 17016713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (dose-dependent)
Number of subjects: 15
Study 17016713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam-induced increase in insular cortex activation
Number of subjects: 15
Study 12654404 — intervention group
Group type: COMPARATOR
Intervention: Partially unblinded placebo-controlled trials
Number of subjects: 0
Study 12654404 — intervention group
Group type: COMPARATOR
Intervention: Partially unblinded active-controlled drug trials
Number of subjects: 0
Study 12654404 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods for estimating preference effects
Number of subjects: 0
Study 12219003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed ePTFE graft
Number of subjects: 48
Study 12219003 — intervention group
Group type: COMPARATOR
Intervention: Standard ePTFE graft
Number of subjects: 48
Study 9605897 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin-rifampin
Number of subjects: 33
Study 9605897 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin-placebo
Number of subjects: 33
Study 7974344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (50% of energy)
Number of subjects: 17
Study 7974344 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 17
Study 2608693 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (8 capsules/day)
Number of subjects: 47
Study 2608693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 capsules)
Number of subjects: 47
Study 128707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipropylacetic acid (DPA)
Number of subjects: 8
Study 128707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipropylacetic acid (DPA) and gamma-aminobutyric acid (GABA)
Number of subjects: 8
Study 31804414 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilization of rib fractures (SSRF) within 72 hours
Number of subjects: 110
Study 31804414 — intervention group
Group type: COMPARATOR
Intervention: Medical management (nonoperative group)
Number of subjects: 110
Study 29695206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 60
Study 29695206 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 60
Study 28231827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (6 months duration) designed to improve strength, balance, and walking retraining.
Number of subjects: 114
Study 28231827 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control group).
Number of subjects: 114
Study 28231827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (6 months duration).
Number of subjects: 114
Study 23506695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin training for three months
Number of subjects: 464
Study 23506695 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 464
Study 21679446 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAT plus learning modules (intervention group)
Number of subjects: 650
Study 21679446 — intervention group
Group type: COMPARATOR
Intervention: Online self-directed learning (control group)
Number of subjects: 650
Study 18446392 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based regimen
Number of subjects: 6105
Study 18446392 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 6105
Study 16443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood glucose (MBG)
Number of subjects: 1441
Study 16443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological variation (BV)
Number of subjects: 1441
Study 16443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose instability (SD of blood glucose [SDBG])
Number of subjects: 1441
Study 15047787 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps program (older adult volunteers serving 15 hours or more per week)
Number of subjects: 1194
Study 15047787 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1194
Study 11505961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,800 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200
Study 11505961 — intervention group
Group type: COMPARATOR
Intervention: 1,700 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200
Study 11505961 — intervention group
Group type: COMPARATOR
Intervention: 2,200 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200
Study 11505961 — intervention group
Group type: COMPARATOR
Intervention: 1,100 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200
Study 9209950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (40 Gy with 5-FU as a sensitizing agent)
Number of subjects: 221
Study 9209950 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of chemotherapy (5-FU and folinic acid)
Number of subjects: 221
Study 9209950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 221
Study 9209950 — intervention group
Group type: COMPARATOR
Intervention: No-adjuvant treatment (control)
Number of subjects: 221
Study 29310653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose soy lecithin (1200 mg/day)
Number of subjects: 96
Study 29310653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose soy lecithin (600 mg/day)
Number of subjects: 96
Study 27359128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived participants
Number of subjects: 0
Study 27359128 — intervention group
Group type: COMPARATOR
Intervention: Well-rested participants
Number of subjects: 0
Study 23946126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic 2% L‐N‐Acetylcysteine (L‐NAC)
Number of subjects: 11
Study 23946126 — intervention group
Group type: COMPARATOR
Intervention: Control ear (no treatment)
Number of subjects: 11
Study 22095569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions (3 annual treatments)
Number of subjects: 12
Study 19334041 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antidepressants
Number of subjects: 3709
Study 19334041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3709
Study 17252311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic amino acids (AAAs)
Number of subjects: 30
Study 17252311 — intervention group
Group type: COMPARATOR
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 30
Study 14734433 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based algorithms for nutritional support in the ICU (implemented in 7 intervention hospitals)
Number of subjects: 499
Study 14734433 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (n = 214)
Number of subjects: 499
Study 11452819 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage after thyroid surgery
Number of subjects: 60
Study 11452819 — intervention group
Group type: COMPARATOR
Intervention: No drainage after thyroid surgery
Number of subjects: 60
Study 9568553 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD) alone
Number of subjects: 4995
Study 9568553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Academic detailing (AD) and Continuous Quality Improvement (CQI) teams
Number of subjects: 4995
Study 9568553 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4995
Study 8067507 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of alcohol consumption
Number of subjects: 0
Study 8067507 — intervention group
Group type: COMPARATOR
Intervention: Actual alcohol consumption
Number of subjects: 0
Study 3055074 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg bolus followed by 50 micrograms/kg/h infusion)
Number of subjects: 8
Study 3055074 — intervention group
Group type: COMPARATOR
Intervention: Control (preservatives of the naloxone preparation)
Number of subjects: 8
Study 5481219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 891
Study 5481219 — intervention group
Group type: COMPARATOR
Intervention: Thermography
Number of subjects: 891
Study 5481219 — intervention group
Group type: COMPARATOR
Intervention: 70-mm mammography
Number of subjects: 891
Study 31912202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous adrenaline
Number of subjects: 8016
Study 31912202 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8016
Study 30715100 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus orthostatic hypotension (OH) measurements
Number of subjects: 4268
Study 30715100 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 (3 minutes) measurement
Number of subjects: 4268
Study 30715100 — intervention group
Group type: EXPERIMENTAL
Intervention: Later measurements of OH
Number of subjects: 4268
Study 30715100 — intervention group
Group type: COMPARATOR
Intervention: BP treatment goal
Number of subjects: 4268
Study 30715100 — intervention group
Group type: EXPERIMENTAL
Intervention: All measures of consensus OH
Number of subjects: 4268
Study 30715100 — intervention group
Group type: EXPERIMENTAL
Intervention: All measurements of OH
Number of subjects: 4268
Study 28398499 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 604
Study 28398499 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 604
Study 28398499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of MYC-R and DHL
Number of subjects: 604
Study 25941982 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial intervention involving undergraduate and doctoral students
Number of subjects: 22
Study 23640665 — intervention group
Group type: COMPARATOR
Intervention: Small-incision open cholecystectomy (SIOC)
Number of subjects: 333
Study 23640665 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 333
Study 23640665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 333
Study 21570660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented humeral fixation
Number of subjects: 161
Study 21570660 — intervention group
Group type: COMPARATOR
Intervention: Uncemented humeral fixation
Number of subjects: 161
Study 18054688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulfate, 80 mg/day)
Number of subjects: 23
Study 18054688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17203478 — intervention group
Group type: EXPERIMENTAL
Intervention: CW (continuous wave EMF)
Number of subjects: 72
Study 17203478 — intervention group
Group type: EXPERIMENTAL
Intervention: PM (pulse modulated EMF)
Number of subjects: 72
Study 17203478 — intervention group
Group type: COMPARATOR
Intervention: SHAM (no EMF)
Number of subjects: 72
Study 15295613 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan monotherapy
Number of subjects: 58
Study 15295613 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus ACEI/amlodipine
Number of subjects: 58
Study 15295613 — intervention group
Group type: COMPARATOR
Intervention: Candesartan plus ACEI
Number of subjects: 58
Study 15295613 — intervention group
Group type: COMPARATOR
Intervention: Candesartan plus amlodipine
Number of subjects: 58
Study 11306743 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus G-CSF
Number of subjects: 38
Study 11306743 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF alone
Number of subjects: 38
Study 11306743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cell contamination presence
Number of subjects: 38
Study 11306743 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of metastasis
Number of subjects: 38
Study 9399229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 91
Study 9399229 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 91
Study 7959290 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical therapy (Group A)
Number of subjects: 8
Study 7959290 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (Group B)
Number of subjects: 8
Study 3605694 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine pretreatment (0.05 mg/kg) followed by succinylcholine (1.5 mg/kg)
Number of subjects: 75
Study 3605694 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml) followed by succinylcholine (1.5 mg/kg)
Number of subjects: 75
Study 3605694 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mg/kg of succinylcholine without d‐tubocurarine pretreatment
Number of subjects: 75
Study 3605694 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine pretreatment (0.05 mg/kg)
Number of subjects: 75
Study 3605694 — intervention group
Group type: COMPARATOR
Intervention: Non-pretreated groups (C‐2 and T‐2)
Number of subjects: 75
Study 31982073 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of combined measles-mumps-rubella-varicella vaccine (MMR+V)
Number of subjects: 0
Study 31982073 — intervention group
Group type: COMPARATOR
Intervention: One dose of monovalent varicella vaccine
Number of subjects: 0
Study 31982073 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+V group
Number of subjects: 0
Study 31982073 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR group
Number of subjects: 0
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose responding self-efficacy assessment
Number of subjects: 424
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing an overdose in the past year
Number of subjects: 424
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with naloxone training
Number of subjects: 424
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving and using naloxone
Number of subjects: 424
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Apprehension with particular response behaviors (e.g. rescue breathing)
Number of subjects: 424
Study 31212214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 424
Study 28100182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod first dose
Number of subjects: 3951
Study 28100182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Holter ECG monitoring
Number of subjects: 3951
Study 26030423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stationary cycling (CYC)
Number of subjects: 33
Study 26030423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rugby small-sided games (SSG)
Number of subjects: 33
Study 26030423 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 23562361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 160
Study 21911572 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHN-490 injection, 1 mg/kg body weight followed by ascending doses of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days respectively in Study 1
Number of subjects: 47
Study 21911572 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHN-490 injection, 15 mg/kg for 5 days in Study 2
Number of subjects: 47
Study 21911572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19622708 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 45
Study 19622708 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 45
Study 17076985 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1000 mg daily for 12 months
Number of subjects: 130
Study 17076985 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1000 mg daily for 24 months
Number of subjects: 130
Study 17076985 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 130
Study 15582080 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (200 microg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour
Number of subjects: 157
Study 15582080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without 5‐fluorouracil and LMWH)
Number of subjects: 157
Study 15582080 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and LMWH
Number of subjects: 157
Study 15582080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 11527868 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision for standard treatment guidelines (STG)
Number of subjects: 62
Study 11527868 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision for stock management
Number of subjects: 62
Study 11527868 — intervention group
Group type: COMPARATOR
Intervention: No supervision (control group)
Number of subjects: 62
Study 9691859 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory examples of two semantic categories presented through headphones during certain stages of the procedure
Number of subjects: 100
Study 9691859 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory examples of two semantic categories presented through headphones during steady-state anaesthesia
Number of subjects: 100
Study 7892419 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 8
Study 7892419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3340471 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled awakenings
Number of subjects: 33
Study 3340471 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic ignoring
Number of subjects: 33
Study 3340471 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 31039765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment as Usual (TAU)
Number of subjects: 160
Study 31039765 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 160
Study 29301585 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker controlled treatment advisory algorithm
Number of subjects: 0
Study 29301585 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26801063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 μg) with standard regimen (0-1-6 month)
Number of subjects: 3
Study 26801063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (60 μg) with 2-dose regimen (0-1 month)
Number of subjects: 3
Study 26801063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (60 μg) with 2-dose regimen (0-2 month)
Number of subjects: 3
Study 23495792 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-fenestrated catheter
Number of subjects: 250
Study 23495792 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 250
Study 21792863 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR testing and first-line treatment with gefitinib
Number of subjects: 0
Study 21792863 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment with gefitinib
Number of subjects: 0
Study 21792863 — intervention group
Group type: COMPARATOR
Intervention: Standard care (first-line treatment with chemotherapy followed by gefitinib as second-line treatment)
Number of subjects: 0
Study 19910718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (3-12 mg/d)
Number of subjects: 0
Study 19910718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17244770 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg oral dose
Number of subjects: 0
Study 15614126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 12
Study 12518491 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 87
Study 12518491 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro
Number of subjects: 87
Study 9784659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 16
Study 9784659 — intervention group
Group type: COMPARATOR
Intervention: Control (no cromolyn sodium)
Number of subjects: 16
Study 7894551 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, an angiotensin-converting enzyme inhibitor, administered 3 to 16 days after acute myocardial infarction.
Number of subjects: 0
Study 2165890 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 12-14 h
Number of subjects: 19
Study 2165890 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 30-36 h
Number of subjects: 19
Study 2165890 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 60-66 h
Number of subjects: 19
Study 356738 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride therapy
Number of subjects: 0
Study 356738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31618863 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of pure whey protein isolate (L)
Number of subjects: 18